Donate Help Contact The AHA Sign In Home
American Heart Association
Stroke
Search: search_blue_button Advanced Search
Stroke. 2003;34:2693-2697
Published online before print October 9, 2003, doi: 10.1161/01.STR.0000096993.90248.27
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/11/2693    most recent
01.STR.0000096993.90248.27v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Christian, J. B.
Right arrow Articles by Toppa, R. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Christian, J. B.
Right arrow Articles by Toppa, R. S.
Related Collections
Right arrow Secondary prevention
Right arrow Embolic stroke
Right arrow Anticoagulants
Right arrow Antiplatelets
Right arrow Epidemiology

(Stroke. 2003;34:2693.)
© 2003 American Heart Association, Inc.


Original Contributions

Racial Disparities in Receipt of Secondary Stroke Prevention Agents Among US Nursing Home Residents

Jennifer B. Christian, PharmD, MPH; Kate L. Lapane, PhD Rebecca S. Toppa, PhD

From Brown University Center for Gerontology and Health Care Research (J.B.C., K.L.L., R.S.T.) and Brown University Department of Community Health (J.B.C., K.L.L.), Providence, RI.

Correspondence to Jennifer B. Christian, PharmD, MPH, Brown University, Box G-B 215M, 171 Meeting St, Providence, RI 02912. E-mail Jennifer_Christian{at}brown.edu

Background and Purpose— Although medications can significantly reduce the risk of recurrent stroke, little is known about the extent to which such therapies are given to nursing home residents. We sought to evaluate the extent to which people of color were less likely to receive pharmacological agents in the treatment of recurrent stroke while living in US nursing homes.

Methods— We identified 19 051 residents with a recent hospitalization and primary discharge diagnosis of 434 or 436 in 5 states from 1992 to 1996; of these, 7053 had concomitant conditions indicating anticoagulant therapy. We considered aspirin, dipyridamole, ticlopidine, or warfarin alone or in combination as secondary drug prevention. Generalized linear models provided estimates of the absolute difference in prevalence estimates of the receipt of agents used for the prevention of recurrent stroke between each race-ethnicity group adjusted for potential confounders.

Results— Variability in use of any treatment was observed by race-ethnicity ranging from 58% of American Indians receiving therapy to only 39% of Asian/Pacific Islanders. Among residents with an indication for anticoagulant therapy, the absolute estimated crude differences indicated that residents of color were less likely than non-Hispanic whites to receive warfarin. After controlling for confounding, Asian/Pacific Islanders, blacks, and Hispanics eligible for anticoagulant therapy received warfarin less often than non-Hispanic white residents.

Conclusions— Overall, only half of our elderly population received any pharmacological agent for secondary prevention of stroke. Interventions designed to improve the pharmacological management of recurrent stroke regardless of race are needed in the nursing home setting.


Key Words: anticoagulants • antiplatelet agents • cerebrovascular accident • ethnology • nursing homes




This article has been cited by other articles:


Home page
J Am Board Fam MedHome page
R. Niska and B. Han
Anticoagulation for Patients with Atrial Fibrillation in Ambulatory Care Settings
J Am Board Fam Med, May 1, 2009; 22(3): 299 - 306.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
D. Kleindorfer
Sociodemographic Groups at Risk: Race/Ethnicity
Stroke, March 1, 2009; 40(3_suppl_1): S75 - S78.
[Full Text] [PDF]


Home page
Am J Health Syst PharmHome page
N. A. Nickman, J. Biskupiak, F. Creekmore, H. Shah, and D. I . Brixner
Antiplatelet medication management in patients hospitalized with ischemic stroke
Am. J. Health Syst. Pharm., November 1, 2007; 64(21): 2250 - 2256.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
D. L. Brown, B. Boden-Albala, K. M. Langa, L. D. Lisabeth, M. Fair, M. A. Smith, R. L. Sacco, and L. B. Morgenstern
Projected costs of ischemic stroke in the United States
Neurology, October 24, 2006; 67(8): 1390 - 1395.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. Xie, E. Q. Wu, Z.-J. Zheng, J. B. Croft, K. J. Greenlund, G. A. Mensah, and D. R. Labarthe
Impact of Stroke on Health-Related Quality of Life in the Noninstitutionalized Population in the United States
Stroke, October 1, 2006; 37(10): 2567 - 2572.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Public HealthHome page
J. Angelelli, D. C. Grabowski, and V. Mor
Effect of Educational Level and Minority Status on Nursing Home Choice After Hospital Discharge
Am J Public Health, July 1, 2006; 96(7): 1249 - 1253.
[Abstract] [Full Text] [PDF]


Home page
StrokeHome page
J. P. Stansbury, H. Jia, L. S. Williams, W. B. Vogel, and P. W. Duncan
Ethnic Disparities in Stroke: Epidemiology, Acute Care, and Postacute Outcomes
Stroke, February 1, 2005; 36(2): 374 - 386.
[Abstract] [Full Text] [PDF]


Home page
Am J EpidemiolHome page
L. B. Morgenstern, M. A. Smith, L. D. Lisabeth, J. M. H. Risser, K. Uchino, N. Garcia, P. J. Longwell, D. A. McFarling, O. Akuwumi, A. Al-Wabil, et al.
Excess Stroke in Mexican Americans Compared with Non-Hispanic Whites: The Brain Attack Surveillance in Corpus Christi Project
Am. J. Epidemiol., August 15, 2004; 160(4): 376 - 383.
[Abstract] [Full Text] [PDF]